Trade

with

Cleveland BioLabs Inc
(NASDAQ: CBLI)
AdChoices
0.4500
-0.0200
-4.26%
After Hours :
-
-
-

Open

0.4715

Previous Close

0.4700

Volume (Avg)

140.47k (232.66k)

Day's Range

0.4203-0.5000

52Wk Range

0.3300-1.49

Market Cap.

26.84M

Dividend Rate ( Yield )

-

Beta

1.61

Shares Outstanding

57.11M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 8.49M

    • Net Income

    • -17.26M

    • Market Cap.

    • 26.84M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -135.11

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.61

    • Forward P/E

    • -0.96

    • Price/Sales

    • 3.05

    • Price/Book Value

    • -4.20

    • Price/Cash flow

    • -1.35

      • EBITDA

      • -22.61M

      • Return on Capital %

      • -60.48

      • Return on Equity %

      • -

      • Return on Assets %

      • -60.48

      • Book Value/Share

      • -0.11

      • Shares Outstanding

      • 57.11M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 2.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -65.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 12.52

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -155.17

            • 39.38

            • Net Profit Margin

            • -135.11

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -205.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.33

              • 2.92

              • Quick Ratio

              • 2.23

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.11

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.26

                • 277.78

                • P/E Ratio 5-Year High

                • -46.09

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.58

                • 124.82

                • Price/Sales Ratio

                • 3.05

                • 9.35

                • Price/Book Value

                • -4.20

                • 8.50

                • Price/Cash Flow Ratio

                • -1.35

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -60.48

                    (-116.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.45

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -23.08M
                  Operating Margin
                  -271.88
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.35
                  Ownership

                  Institutional Ownership

                  5.43%

                  Top 10 Institutions

                  5.09%

                  Mutual Fund Ownership

                  2.85%

                  Float

                  94.41%

                  5% / Insider Ownership

                  6.10%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Extended Market Index Fund

                  •  

                    778,032

                  • 2.35

                  • 1.36

                  • Vanguard Total Stock Mkt Idx

                  •  

                    563,893

                  • 0.00

                  • 0.99

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    93,847

                  • 0.00

                  • 0.16

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    35,489

                  • 0.00

                  • 0.06

                  • Vanguard Instl Total Stock Market Index

                  •  

                    35,300

                  • 0.00

                  • 0.06

                  • Vanguard Balanced Index Fund

                  •  

                    30,867

                  • -8.81

                  • 0.05

                  • Vanguard Growth and Income Fund

                  •  

                    22,800

                  • 0.00

                  • 0.04

                  • Master Extended Market Index Series

                  •  

                    20,827

                  • 0.00

                  • 0.04

                  • USAA Extended Market Index Fund

                  •  

                    20,818

                  • -0.04

                  • 0.04

                  • Vanguard US Equity Index

                  •  

                    10,323

                  • 1,082.47

                  • 0.02

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    1,403,620

                  • +2.46%

                  • 2.46

                  • Ladenburg Thalmann Asset Management Inc

                  •  

                    721,200

                  • 0.00%

                  • 1.26

                  • Sabby Management LLC

                  •  

                    306,165

                  • -83.23%

                  • 0.54

                  • Geode Capital Management, LLC

                  •  

                    132,540

                  • 0.00%

                  • 0.23

                  • California Public Employees Retrmnt Sys

                  •  

                    114,307

                  • 0.00%

                  • 0.20

                  • Northern Trust Investments, N.A.

                  •  

                    71,508

                  • -0.90%

                  • 0.13

                  • D. E. Shaw & Co LP

                  •  

                    67,041

                  • 0.00%

                  • 0.12

                  • Renaissance Technologies Corp

                  •  

                    38,200

                  • -21.52%

                  • 0.07

                  • Atlanta Capital Group

                  •  

                    25,000

                  • 0.00%

                  • 0.04

                  • Guggenheim Capital LLC

                  •  

                    23,549

                  • -9.09%

                  • 0.04

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Cleveland BioLabs, Inc., was incorporated in Delaware in June 2003 as a spin-off company from the Cleveland Clinic Foundation. It is adrug development company seeking to develop first-in-class pharmaceuticals designed to address dise...moreases with significant unmet medical need. Its programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells. It conducts business in the United States and the Russian Federation and have worldwide development and commercialization rights to all of its product candidates, subject to certain financial obligations to its current licensors. Its lead product candidates are Entolimod, which the Company is developing as a radiati...moreon countermeasure and an oncology drug, and Curaxin CBL0137, its lead oncology product candidate. The Company also has an additional clinical stage program and multiple projects in different stages of preclinical drug development. Entolimod, is its most advanced product candidate, a Toll-like receptor 5, or TLR5, agonist, which the Company is developing as a radiation countermeasure for prevention of death from Acute Radiation Syndrome, or ARS, and as an oncology drug. Curaxin CBL0137, is its lead oncology product candidate, that acts through a novel mechanism enabling this compound to simultaneously target three molecular pathways within cancer cells. It competes with both biotechnology and major pharmaceutical companies. Government authorities in the U.S. and in other countries, regulate the research, development, testing, manufacture, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, quality control, labeling and export and import of pharmaceutical products such as those that the Company is developing.lessless

                  Key People

                  Dr. Yakov Kogan,PhD

                  CEO/Director

                  Mr. C. Neil Lyons

                  CFO/Chief Accounting Officer

                  Ms. Leah Brownlee

                  Secretary/Vice President, Divisional

                  Rachel Levine

                  Vice President, Divisional

                  Mr. James J. Antal

                  Director

                  • Cleveland BioLabs Inc

                  • 73 High Street

                  • Buffalo, NY 14203

                  • USA.Map

                  • Phone: +1 716 849-6810

                  • Fax: +1 716 849-6820

                  • cbiolabs.com

                  Incorporated

                  2003

                  Employees

                  44

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: